Knopp Biosciences Announces Year 3 Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Activators in Rare Neonatal Epilepsy
Knopp Biosciences LLC today announced the renewal of its grant award for Year 3 from the National Institutes of Health Blueprint Neurotherapeutics Network (BPN) to advance novel treatments for epilepsy.
Based on milestone attainment, Knopp was awarded an additional $693,000 in direct support. The grant has a total potential value of $2.3 million over four years. Beyond direct support, the NIH BPN may underwrite the cost of key external studies at BPN-sponsored-contract research organizations.
As previously reported, Knopp is directing its Kv7 potassium channel activator program to the discovery and development of best-in-class small-molecule drug candidates, consistent with the goals of the NIH BPN. The BPN, part of the NIH Blueprint for Neuroscience Research, is a collaboration of NIH Institutes and Centers that supports research on the nervous system with the goal of developing new neurotherapeutic drugs.
These novel molecules have been synthesized to modulate an anti-seizure pharmaceutical target encoded by the KCNQ2 gene, which contributes significantly to early brain development. Knopp intends to first advance its novel KCNQ2 activators in neonatal epileptic encephalopathy, a rare disorder caused by sporadic mutations in the KCNQ2 gene. Neonatal epileptic encephalopathy is characterized by persistent seizures from the beginning of life and profound developmental disability in children for whom current anti-seizure medications are insufficient or ineffective.
Knopp President and CEO Michael Bozik, M.D., a neurologist with clinical development expertise in potassium channel modulators, serves as Principal Investigator on the NIH BPN grant. He said, "We’re very pleased to receive this latest Blueprint award, which provides ongoing support that will help us advance promising clinical drug candidates to treat a rare and devastating disease without approved treatment options.” He said Knopp expects its first KCNQ2 candidate to enter Phase 1 testing in 2019.
Knopp is collaborating with key clinical investigators in the development of its first candidate, as well as with the KCNQ2 Cure Alliance, whose 2018 Family and Professional Summit will be held Sept. 14-16, 2018, in Anaheim, CA.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit knoppbio.com.
The Blueprint Neurotherapeutics Network provides non-dilutive support for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. Please visit BPN.
ABOUT KCNQ2 CURE ALLIANCE
KCNQ2 Cure Alliance is a non-profit organization dedicated to raising research funds for KCNQ2 epileptic encephalopathy, a rare and catastrophic form of epilepsy beginning in the first days of life. Please visit kcnq2cure.org.
Knopp's Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
PEI-Genesis Approved as Category C Distributor for All Conesys Product Lines14.11.2018 11:15 | Pressemelding
PEI-Genesis, the world’s fastest assembler of precision connectors, has been approved as a Category C Distributor for all Conesys product lines. PEI-Genesis will be assembling all government approved Mil-Circular connector product lines manufactured by Conesys at the company’s South Bend, IN facility. “The addition of Conesys Mil-Circular connectors gives global, value-added access to all customers and adds to the breadth of Conesys’ offerings,” said Peter Austin, PEI-Genesis’s Senior Vice President of Manufacturing, Product Management, Marketing, & Training. “The new partnership will give Conesys access to our award-winning service and largest available-to-sell connector inventory.” PEI-Genesis has inventory to assemble Conesys connectors now, and will be able to assemble over 50,000 military connector part numbers from Conesys inventory very soon. Product families being assembled by PEI-Genesis for Conesys include the MIL-DTL-38999, MIL-DTL-26482, MIL-DTL-83723, and MIL-DTL-26500. “W
Jam City and Disney Announce Multi-Year Mobile Games Development Partnership14.11.2018 11:00 | Pressemelding
Jam City, a leader in mobile entertainment, today announced a multi-year mobile games development partnership with Disney that includes Jam City taking over Disney’s popular mobile game, Disney Emoji Blitz. Members of Disney’s Glendale Games Studio will join Jam City and continue to operate and grow Disney Emoji Blitz as part of the Jam City team. Jam City will also have the right to develop new mobile games based on iconic characters and stories from Pixar and Walt Disney Animation Studios. The first game Jam City and Disney plan to develop is a mobile game based on Disney Animation’s Frozen sequel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005011/en/ Jam City and Disney Announce Multi-Year Mobile Games Development Partnership (Graphic: Business Wire) “Jam City is proud to be teaming with Disney,” said Chris DeWolfe, co-founder and CEO of Jam City. “Disney is the world’s leader in beloved characters and brands th
Successful 2018 Chinese Food Festival Celebrates International Culture and Development at United Nations14.11.2018 11:00 | Pressemelding
The 2018 Chinese Food Festival at the United Nations concluded successfully last Friday inside the Delegates Dining Room of New York’s United Nations Headquarters. Thousands of UN officials, socialites, celebrities and New Yorkers enjoyed performances, demonstrations and a distinguished dining experience with authentic food and exquisite wine from China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005297/en/ Ms. María Fernanda Espinosa, President of the 73rd UN General Assembly, joined Mr. Cao Kailong and others at the Chinese Food Festival inside the United Nations (Photo: Business Wire) The week-long food and wine festival opened with a cocktail reception, attended by 300 VIP guests. Actor, Juan Carlos Espinosa of Narcos, commented “This is an incredible experience, getting to experience the culture, food and wine of Ningxia. I am so impressed with the food and richness of the wine”. Other guests included Under-Se
Bearingpoint Acquires Inpuls, a Leading Data Specialist in Belgium14.11.2018 09:20 | Pressemelding
Management and technology consultancy BearingPoint has made a strategic move in the Belgian consulting market by acquiring Inpuls, a leading data specialist. The acquisition contributes to BearingPoint’s overall growth objectives, strengthens its presence in Belgium, and enhances its data capabilities. “The acquisition of Inpuls pays into two core elements of our corporate strategy: we enrich our portfolio focused on digitalization, regulation, and analytics; we concentrate on European clients, enabling them to become global leaders. Against this background this acquisition doubles our size in Belgium, and just as important, our clients now have Inpuls’s data expertise. We believe data is at the heart of digital transformation and creates value propositions and competitive advantages for our clients,” said Kiumars Hamidian, Managing Partner of BearingPoint. Founded in 2014, Inpuls is a Belgian consultancy specialized in data strategy, data governance, privacy, Big Data, and analytics.
GSMA Announces New Developments for MWC19 Barcelona14.11.2018 09:00 | Pressemelding
The GSMA today announced further details for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “We have an amazing show lined up for February, with more than 2,400 companies participating across the exhibition, four days of conference programming and so many other events and activities taking place at MWC19,” said Michael O’Hara, Chief Marketing Officer, GSMA. “With in-depth examination of topics such as 5G, artificial intelligence, Internet of Things, content, security and many others, MWC Barcelona, now more than ever, is the “must-attend” industry event.” Execs from ARM, Huawei, KT and Orange Confirmed for Keynotes The GSMA announced several newly confirmed keynote speakers fo
Exclusive Group and Arcitura Education Team Up for Channel Partners to Profit from Cloud Skills Gap14.11.2018 08:00 | Pressemelding
Exclusive Group, the value-added services and technologies (VAST) group, today announced an agreement to become the only global provider of Arcitura Education’s renowned, vendor-neutral Cloud Certified Professional (CCP) accreditation programme. The move underlines the unique value of Exclusive Group’s ‘Cloud Competency Centre’ and will enable thousands more channel partners to develop the skills necessary to meet evolving customer challenges around cloud transformation and convert significant additional revenues. “Channel partners can’t afford to lose their market edge through a lack of cloud competency – they need new skills to complement their experience and technology knowledge so that customers carry on seeing them as relevant to their future,” said Andre Dieball, Global Director, Services at Exclusive Group. “70-80% of enterprises are experiencing cloud skills crises that risk crucial transformation projects going over time and over budget. These projects, collectively worth bill